CA2032158A1 - Multivalent repressor of gene function - Google Patents

Multivalent repressor of gene function

Info

Publication number
CA2032158A1
CA2032158A1 CA002032158A CA2032158A CA2032158A1 CA 2032158 A1 CA2032158 A1 CA 2032158A1 CA 002032158 A CA002032158 A CA 002032158A CA 2032158 A CA2032158 A CA 2032158A CA 2032158 A1 CA2032158 A1 CA 2032158A1
Authority
CA
Canada
Prior art keywords
viral
htlv
hiv
rev
transdominant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002032158A
Other languages
French (fr)
Other versions
CA2032158C (en
Inventor
Helmut Bachmayer
Ernst Boehnlein
Bryan R. Cullen
Warner C. Greene
Joachim Hauber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Duke University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898915602A external-priority patent/GB8915602D0/en
Priority claimed from GB898924396A external-priority patent/GB8924396D0/en
Application filed by Individual filed Critical Individual
Publication of CA2032158A1 publication Critical patent/CA2032158A1/en
Application granted granted Critical
Publication of CA2032158C publication Critical patent/CA2032158C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Transdominant repressors of viral gene phenotypic expression derived from the rev gene product of HIV-1 or the rex gene product of HTLV-1 and corresponding mutated genes are described, having the capability of repressing the Rev function in HIV-1 and/or the Rex function in HTLV-I and HTLV-II. Transient gene expression analysis of a series of missense and deletion mutants has been used.

Some of the mutants found repress both the Rev and the Rex function and are thus active in more than one viral species.

Transdominant viral mutants represent a promising new class of anti-viral agents. Cellular expression of these transdominant inhibitors may be used in such therapeutic approaches as intracellular immunization in order to protect cells against the deleterious effects of viral, e.g.
HIV-1 infection.
CA002032158A 1989-05-25 1990-05-23 Multivalent repressor of gene function Expired - Lifetime CA2032158C (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US35687889A 1989-05-25 1989-05-25
US356,878 1989-05-25
GB898915602A GB8915602D0 (en) 1989-07-07 1989-07-07 Multivalent repressor of gene function
GB8915602.0 1989-07-07
GB8924396.8 1989-10-30
GB898924396A GB8924396D0 (en) 1989-10-30 1989-10-30 Multivalent repressor of gene function
US44267089A 1989-11-29 1989-11-29
US442,670 1989-11-29
PCT/EP1990/000831 WO1990014427A2 (en) 1989-05-25 1990-05-23 Multivalent repressor of gene function

Publications (2)

Publication Number Publication Date
CA2032158A1 true CA2032158A1 (en) 1990-11-26
CA2032158C CA2032158C (en) 2009-09-15

Family

ID=27450368

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002032158A Expired - Lifetime CA2032158C (en) 1989-05-25 1990-05-23 Multivalent repressor of gene function

Country Status (13)

Country Link
EP (1) EP0406557B1 (en)
JP (2) JP3126378B2 (en)
KR (1) KR100215949B1 (en)
AT (1) ATE207122T1 (en)
AU (2) AU648256B2 (en)
CA (1) CA2032158C (en)
DE (1) DE69033829T2 (en)
DK (1) DK0406557T3 (en)
ES (1) ES2166748T3 (en)
FI (1) FI110437B (en)
HU (2) HU217091B (en)
IL (1) IL94482A (en)
WO (1) WO1990014427A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006990A1 (en) * 1990-10-17 1992-04-30 The United States Of America, Represented By The Secretary, United States Department Of Commerce Molecular clones of hiv-1 and uses thereof
US5534408A (en) * 1993-09-24 1996-07-09 University Of Massachusetts Medical Center 2-deoxystreptamine aminoglycoside inhibition of HIV RRE/Rev binding
US5650306A (en) * 1993-06-07 1997-07-22 University Of Michigan Recombinant nucleic acids for inhibiting HIV gene expression
WO1995004546A1 (en) * 1993-08-06 1995-02-16 Kai Juhani Ernst Krohn Novel mutated human and simian immunodeficiency viruses and vaccines containing said viruses
US6228369B1 (en) 1993-12-13 2001-05-08 Transgene S.A. Composition of trans-dominant variants of viral proteins for obtaining an anti-viral effect
US5981258A (en) * 1993-12-13 1999-11-09 Transgene S.A. Composition of trans-dominant variants of viral proteins for obtaining an antiviral effect
FR2713651B1 (en) * 1993-12-13 1996-04-19 Transgene Sa New composition for an antiviral effect.
CN1991365A (en) 1996-01-26 2007-07-04 沃尔科股份有限公司 Method of managing the chemotherapy of patients who are HIV positive based on the phenotypic drug sensitivity of human hiv strains
CA2254819A1 (en) * 1996-06-06 1997-12-11 Novartis Ag Inhibition of hiv-1 replication by antisense rna expression
NZ333188A (en) * 1996-06-06 2001-06-29 Systemix Inc Use of DNA scaffold attachments regions to modify expression of a heterologous gene
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
AU770885B2 (en) * 1998-12-22 2004-03-04 Ppd Development, Lp Genetic suppressor elements against human immunodeficiency virus
AU2493300A (en) * 1999-01-06 2000-07-24 Regents Of The University Of California, The Modulation of hiv replication using sam68
US7300790B2 (en) 2003-01-23 2007-11-27 Iogenetics, Llc Transgenic animals expressing transdominant negative retroviral nucleic acids and proteins
JP5653549B1 (en) 2014-05-30 2015-01-14 株式会社松風 Ion sustained release dental resin temporary sealant composition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935372A (en) * 1986-05-20 1990-06-19 Dana Farber Cancer Institute Art nucleotide segments, vectors, cell lines methods of preparation and use

Also Published As

Publication number Publication date
AU678478B2 (en) 1997-05-29
AU5738890A (en) 1990-12-18
CA2032158C (en) 2009-09-15
HUT56135A (en) 1991-07-29
ES2166748T3 (en) 2002-05-01
IL94482A0 (en) 1991-03-10
EP0406557B1 (en) 2001-10-17
DK0406557T3 (en) 2002-02-11
KR100215949B1 (en) 1999-08-16
AU6757394A (en) 1994-11-17
WO1990014427A3 (en) 1991-01-10
EP0406557A3 (en) 1991-05-02
FI110437B (en) 2003-01-31
DE69033829D1 (en) 2001-11-22
JP3126378B2 (en) 2001-01-22
HU904245D0 (en) 1991-06-28
KR920701440A (en) 1992-08-11
DE69033829T2 (en) 2002-04-04
HU217091B (en) 1999-11-29
FI910371A0 (en) 1991-01-24
JPH10165188A (en) 1998-06-23
IL94482A (en) 2003-09-17
JPH04500009A (en) 1992-01-09
ATE207122T1 (en) 2001-11-15
JP3159671B2 (en) 2001-04-23
WO1990014427A2 (en) 1990-11-29
HU211530A9 (en) 1995-11-28
EP0406557A2 (en) 1991-01-09
AU648256B2 (en) 1994-04-21

Similar Documents

Publication Publication Date Title
CA2032158A1 (en) Multivalent repressor of gene function
CA2051562A1 (en) Bacillus thuringiensis isolates active against dipteran pests
BG102048A (en) Tetrahydrofuran-containing sulphonamides as aspartylprotease inhibitors
HUP0203075A2 (en) Aromatic diamide derivatives or salts thereof, agricultural/horticultural chemicals and method of using the same
DE69115129D1 (en) Compositions of cubic perovskite crystal structure, process for their preparation and products made therefrom.
CY1106178T1 (en) 2'- SUBSTITUTED 1,1'-BIPHENYL-2-CARBOXAMIDES, METHOD FOR THEIR PREPARATION, THEIR USE AS A MEDICINE AS WELL AS PHARMACEUTICAL PREPARATIONS COMPRISING THEM
CA2051288A1 (en) Viral targeted destruction of neoplastic cells
DK1056771T3 (en) Streptogramin derivatives, their preparation and preparations containing them
AU2253288A (en) Expression vectors for the synthesis of proteins and plasmid replicons and sequence cassettes for use in constructing such vectors
GR1000639B (en) Preparation process for the tonsillitis treatment
IT8019677A0 (en) APPARATUS FOR HANDLING A PLURALITY OF ITEMS.
HUP0300557A2 (en) N-deacetylthiocolchicine derivatives and pharmaceutical compositions containing them
EP0474797A4 (en) Protein having a transactivating property, vectors expressing this protein, cell lines, and uses thereof
EP0314042A3 (en) Novel copolymers and superoxide dismutase modified with said copolymers
Michailova Polytene chromosomes of different subfamilies of family Chironomidae, Diptera
SU872166A1 (en) Method of restoration the worn surface of articles
DE69434019D1 (en) COMPOSITION OF TRANSDOMINANT VARIANTS OF VIRUS PROTEINS FOR ANTIVIRAL EFFECT
IT1234895B (en) POLARIZATION NETWORK FOR COUPLES OF INTEGRATED AMPLIFIERS SWITCHED FROM AN ASYMMETRIC CONFIGURATION TO A BRIDGE AND VICEVERSA CONFIGURATION.
Yamada Strain Aging of High C Steel Wires
Laveine Importance of understanding of the architecture of frond for systematics of Neuropteridae and Callipteridiaceae and its stratigraphic implications
CA2003794A1 (en) Expression of hiv proteins in drosophila cells
IT7985508A0 (en) MECHANICAL EQUIPMENT FOR TILTING TILES OR SIMILAR BRICKS BY 90 DEGREES AND ARRANGE THEM IN GROUPS.
JPS51138918A (en) Method of making ease assembly work of instrusion type pipe-coupling
IT210680Z2 (en) EXPULSOR GROUP FOR MACHINES FOR HANDLING SIGNATURES AND RELATED ITEMS, PARTICULARLY MACHINES FOR STACKING SIGNATURES
GB1458586A (en) Antiviral complexes of double stranded rna and its derivatives

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry